IMPACT

 Funding innovative world-class cancer research. 

  Inspire the community to fund breakthrough cancer research and treatment initiatives to enhance quality of life. 

Multiple Myeloma Adoptive T-Cell Therapy Clinical Trial

• This is a first in-human study, representing the culmination of a long path from bench research to bedside that began in 1987. The Phase 1 clinical trial, will be conducted at the Nyberg Human Cellular Therapy Lab and will enroll 18 patients with relapsed or refractory multiple myeloma. 
• The primary objectives are to determine the toxicity, feasibility and success rate of in-house manufacturing and administration of MUC1-specific T-cells in patients with multiple myeloma. 

· 

The end goal will be creation of a clinical protocol and manufacturing components for submission as an Investigational New Drug (IND) application to the FDA.

AZ Rare Cancer initiative over a 2-year period designed to achieve three goals:

• Understand the individual biology of rare and refractory cancers.
• Develop tests to understand who is vulnerable to developing these cancers.
• Provide novel, effective precision medicine treatments, including new targeted drugs, immunotherapies, and cellular therapies.

Specific research will focus on a series of uncommon cancers for which HHRI has recognized expertise, including uveal melanoma and small cell carcinoma of the ovary, two cancers for which there are no FDA approved treatments.